85 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 May 24
Cogent Biosciences Reports First Quarter 2024 Financial Results
8:19am
Expenses: Research and development expenses were $52.7 million for the first quarter of 2024 compared to $36.0 million for the first quarter of 2023 … ,
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Interest income
8-K
EX-99.1
15lj12 afnd4muojmehf
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
8-K
EX-99.1
9w6boss
14 Feb 24
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
8:35am
8-K
EX-99.1
h91c 7jkv
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
8-K
EX-99.1
g3dngzrr9gdss mjw
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
424B5
515p0l6
8 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
4vvuu
6 Jun 23
Prospectus supplement for primary offering
5:22pm
8-K
EX-99.1
e4zc5t 1zmx8e7
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
8-K
EX-99.2
fp7bqt1n7m78uv
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
4crkhozbc ldrc
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am